To assess the benefit of interferon (IFN)-alpha therapy in malignant melanoma.
Results of the review
Nine randomised trials were identified, of which one was unpublished. One trial was excluded from the analysis. None of the eight included trials were placebo-controlled. The number of participants in each study ranged from 96 to 654 (total = 3,178).
The quality assessment scores for the studies ranged from 22 to 71 out of a maximum of 81. The mean score was 55.4 (95% CI: 53.8, 57).
Overall survival (6 trials, n=2,771): only one of the primary studies reported a significant impact of IFN-alpha on overall survival, but the reviewers' analysis did not confirm this. The authors calculated the NNT for this data; it did not reach statistical significance.
Disease-free survival (4 trials, n=2,020): one trial found that IFN-alpha was associated with improved disease-free survival, and the reviewers' analysis confirmed this. Another trial found improved disease-free survival only with highdose IFN-alpha, but this was not confirmed by the reviewers' analysis. Two other trials had inconclusive findings.
Relapse (4 trials, n=1,704): fewer patients treated with IFN-alpha developed metastases compared with the controls (46.9% versus 54.9%, respectively; CIs not provided). The relapse rates ranged from 24 to 58.8% in the groups receiving IFN-alpha, compared with 36.3 to 64.9% in the controls. The ranges overlapped, but the authors did not pool the data because of heterogeneity; therefore, the groups were not compared statistically. Only one trial found a statistically-significant difference in the relapse rates. This favoured low-dose adjuvant IFN-alpha over standard treatment (odds ratio 0.55, 95% CI: 0.34, 0.91; NNT 9, 95% CI: 5, 46). Toxicity: discontinuation of the treatment due to adverse effects ranged from 3.2 to 35% (reported in 3 trials). Dose reductions ranged from 5.2 to 59% (reported in 4 studies). Two drug-related deaths were reported overall.
Authors' conclusions
There is no clear benefit of IFN-alpha therapy on overall survival in melanoma patients. A large randomised trial is needed to assess whether a full regimen of IFN-alpha is effective, and to identify subgroups who may benefit from treatment.
CRD commentary
The research question was clearly defined in this review, although some of the inclusion and exclusion criteria could have been specified in more detail. For instance, the authors did not fully rationalise why only IFN-alpha monotherapy was eligible. This may limit the clinical applicability of the findings.
The search strategy was reasonable, although the authors did not search Cancerlit. The authors attempted to identify unpublished material and there were no language restrictions. This suggests that most of the relevant studies are likely to have been identified. However, publication bias was not assessed. In general, the inclusion and exclusion criteria and methods for assessing validity were described adequately, although the authors did not provide details about how the studies were selected or how many of the reviewers performed the study selection and quality assessment processes. This makes it difficult to assess the quality of the review.
The studies included may have been of limited quality. One of the nine studies identified was excluded without clear reason. None of the studies included were placebo-controlled. The authors state that details of the participants, disease characteristics, study designs and outcomes were not always clearly reported in the primary studies.
The authors did not describe potential biases that could affect the findings of the review. A narrative synthesis was provided, supplemented by summary statistics in a table. This is likely to be appropriate given the (stated) heterogeneity of the data. The authors calculated summary statistics for individual studies, which could have been better presented in the narrative summary.
There are also some difficulties with the outcomes used. The authors did not report the statistical significance of median survival for the individual studies, or state how disease-free survival was analysed. Using outcomes that count the number of participants is problematic in cancer studies, as this does not account for confounding and differences in the time period over which the participants were recruited. A better outcome measure may have been to compare time to events using the Kaplan-Meier method (life tables). It is also possible that non significant findings are due to the sample size of the included studies. Care should be taken when interpreting the findings of small and heterogeneous studies.
Overall, the data appear to support the authors' general conclusions, although the lack of detail about the included studies makes it difficult to assess the generalisability of the findings.
Implications of the review for practice and research
Practice: The authors suggest there is no evidence that IFN-alpha has a clear survival benefit for people with high-risk melanoma.
Research: The authors suggest that a large randomised trial is needed to assess whether a full regimen of IFN-alpha is effective, and to identify subgroups of patients who may benefit from treatment. 
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